AlphaCentric Advisors’s Cogent Biosciences COGT Stock Holding History

AlphaCentric Advisors’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$322K	Sell	37,500 -96,975	-72%	-$843K	0.09%	79
2021 Q3	$1.13M	Buy	134,475 +11,975	+10%	+$91.8K	0.29%	22
2021 Q2	$993K	Buy	122,500 +32,500	+36%	+$275K	0.27%	26
2021 Q1	$790K	Buy	90,000 +70,300	+357%	+$677K	0.27%	30
2020 Q4	$221K	Buy	+19,700	New	+$216K	0.09%	61

Other funds holding COGT

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

AlphaCentric Advisors's COGT Position: Q4 2021 in Review

AlphaCentric Advisors reduced its Cogent Biosciences (COGT) stake by 72% in Q4 2021, selling an estimated $843K and leaving 37,500 shares worth $322K. The position accounts for 0.09% of the portfolio, ranked #79.

AlphaCentric Advisors first reported a position in COGT in Q4 2020 and has held it in 5 quarters since. The position peaked at $1.13M in Q3 2021. 82 funds tracked by Wall St. Rank hold COGT as of Q4 2021.

AlphaCentric Advisors held 37,500 shares of Cogent Biosciences worth $322K as of Q4 2021.
AlphaCentric Advisors sold 96,975 Cogent Biosciences shares in Q4 2021, an estimated $843K.
Cogent Biosciences made up 0.09% of AlphaCentric Advisors's portfolio in Q4 2021, its #79 holding.
AlphaCentric Advisors first reported a position in Cogent Biosciences in Q4 2020 and has held it in 5 quarters since.
AlphaCentric Advisors's Cogent Biosciences position peaked at $1.13M in Q3 2021.
82 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2021.

Based on AlphaCentric Advisors's 13F filing for Q4 2021, filed 25 Feb 2022.